Afimmune KOL Event on Sickle Cell Disease: The Changing Landscape and Need for New Treatments
About The Event
Join us for a virtual expert panel discussion on Sickle Cell Disease (SCD), featuring key opinion leaders Biree Andemariam, MD (University of Connecticut; Sickle Cell Disease Association of America) and Vivien Sheehan, MD, PhD (Emory University) who will discuss the treatment landscape and large unmet medical need in treating patients who suffer from SCD.
The event will also feature an update from Afimmune on their clinical development plans for Epeleuton, a novel synthetic fatty acid drug product which has been shown to have a unique dual mechanism of action for the treatment of SCD, targeting factors affecting severity, course of disease, and vaso-occlusive crisis risk.
Epeleuton has received orphan drug designation for the treatment of SCD from the FDA and EMA.
A live question and answer session will follow the formal presentations.